

**GENERAL POSTER SESSIONS****Zevalin<sup>®</sup>****Lymphoma and Plasma Cell Disorders  
Saturday, May 31, 2008**

*Poster Display* 8:00am – 12:00pm S Hall A1

**[Poster 47D, Abstract 8565]** Phase I trial of yttrium 90 ibritumomab tiuxetan (90Y-RIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).

**Presenter: Lode J. Swinnen, MD**

**[Poster 56E, Abstract 8615]** Yttrium-90 ibritumomab tiuxetan combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for relapsed/refractory B-cell non-Hodgkin's lymphoma.

**Presenter: L Alexander Shimabukuro-Vornhagen, MD**

**Developmental Therapeutics: Immunotherapy  
Sunday, June 1, 2008**

*Poster Display* 2:00pm – 6:00pm S Hall A1

**[Poster 20D, Abstract 3075]** Retrospective study of RIT (radiolabelled immunotherapy) with <sup>90</sup>Y-IT (<sup>90</sup>Y-ibritumomab tiuxetan) in relapsing FL (follicular lymphoma) after autologous (BM) bone marrow transplant (ABMT).

**Presenter: Frédéric Peyrade**

**OPAXIO<sup>™</sup>****Breast Cancer — Metastatic  
Monday, June 2, 2008**

*Poster Display* 2:00pm – 6:00pm S Hall A1

**[Poster 32A, Abstract 1063]** Phase II trial of paclitaxel poliglumex (PPX) with capecitabine (C) for metastatic breast cancer (MBC).

**Presenter: Donald W. Northfelt, MD, FACP**